Drs John Kane and Jonathan M. Meyer discuss what new antipsychotic drugs are available for schizophrenia. What drugs are under development? And what do they potentially offer?

Relevant disclosures can be found with the episode show notes on Medscape (https://www.medscape.com/viewarticle/969528). The topics and discussions are planned, produced, and reviewed independently of advertiser. This podcast is intended only for US healthcare professionals.

Resources

The Clozapine Handbook: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) New Edition https://www.amazon.com/Clozapine-Handbook-Handbooks-Essential-Psychopharmacology/dp/1108447465

The Clinical Use of Antipsychotic Plasma Levels: Stahl's Handbooks (Stahl's Essential Psychopharmacology Handbooks) Kindle Edition https://www.amazon.com/Clinical-Antipsychotic-Plasma-Levels-Psychopharmacology-ebook-dp-B09B3VMM8N/dp/B09B3VMM8N

Clinical Use of Reserpine in Psychiatry: Comparison With Chlorpromazine https://nyaspubs.onlinelibrary.wiley.com/doi/epdf/10.1111/j.1749-6632.1955.tb42463.x

Arvid Carlsson https://www.nobelprize.org/prizes/medicine/2000/carlsson/facts/

Clozapine: Guidelines for Clinical Management https://pubmed.ncbi.nlm.nih.gov/2670914/

Clozapine: Medscape Drugs & Diseases https://reference.medscape.com/drug/clozaril-versacloz-clozapine-342972

Tardive Dyskinesia Prevalence in the Period of Second-Generation Antipsychotic Use: A Meta-analysis https://www.psychiatrist.com/jcp/movement-disorder/tardive-dyskinesia-prevalence/

Efficacy and Safety of Lumateperone for Treatment of Schizophrenia — A Randomized Clinical Trial https://jamanetwork.com/journals/jamapsychiatry/fullarticle/2758022

Trace Amine-Associated Receptor 1 (TAAR1): Molecular and Clinical Insights for the Treatment of Schizophrenia and Related Comorbidities https://pubs.acs.org/doi/10.1021/acsptsci.2c00016

Trace Amine-Associated Receptor 1 Modulates Dopaminergic Activity https://jpet.aspetjournals.org/content/324/3/948.long

A Non-D2-Receptor-Binding Drug for the Treatment of Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa1911772

A Clinical Study to Evaluate the Long-term Safety and Tolerability of an Investigational Drug in People With Schizophrenia https://clinicaltrials.gov/ct2/show/NCT04109950

A Study to Assess the Effects of RO6889450 (Ralmitaront) in Participants With Schizophrenia or Schizoaffective Disorder and Negative Symptoms https://clinicaltrials.gov/ct2/show/NCT03669640

Emerging Schizophrenia Drugs Target Negative Symptoms https://www.medscape.com/viewarticle/953336

Selective Muscarinic Receptor Agonist Xanomeline as a Novel Treatment Approach for Schizophrenia https://ajp.psychiatryonline.org/doi/10.1176/appi.ajp.2008.06091591

Muscarinic Cholinergic Receptor Agonist and Peripheral Antagonist for Schizophrenia https://www.nejm.org/doi/10.1056/NEJMoa2017015

Risperidone, 2 mg/day vs. 4 mg/day, in First-Episode, Acutely Psychotic Patients: Treatment Efficacy and Effects on Fine Motor Functioning https://www.psychiatrist.com/jcp/schizophrenia/risperidone-mgday-vs-mgday-episode-acutely-psychotic/